| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences.
|
Gastroenterology
|
2004
|
14.78
|
|
2
|
Infliximab, azathioprine, or combination therapy for Crohn's disease.
|
N Engl J Med
|
2010
|
12.35
|
|
3
|
Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD.
|
Gastrointest Endosc
|
2004
|
4.12
|
|
4
|
Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis.
|
Am J Gastroenterol
|
2011
|
3.97
|
|
5
|
A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis.
|
Gastroenterology
|
2006
|
3.68
|
|
6
|
A deep profiler's guide to cytometry.
|
Trends Immunol
|
2012
|
3.14
|
|
7
|
Mucosal healing in inflammatory bowel diseases: a systematic review.
|
Gut
|
2012
|
3.02
|
|
8
|
Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis.
|
Gastroenterology
|
2011
|
2.96
|
|
9
|
The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?
|
Am J Gastroenterol
|
2010
|
2.74
|
|
10
|
Once-daily, high-concentration MMX mesalamine in active ulcerative colitis.
|
Gastroenterology
|
2006
|
2.34
|
|
11
|
Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis.
|
Gut
|
2009
|
2.08
|
|
12
|
Clinical recovery from surgery correlates with single-cell immune signatures.
|
Sci Transl Med
|
2014
|
1.62
|
|
13
|
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target.
|
Am J Gastroenterol
|
2015
|
1.44
|
|
14
|
Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies.
|
Lancet
|
2017
|
1.39
|
|
15
|
Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial.
|
Gut
|
2006
|
1.32
|
|
16
|
Comparative proteomic studies on the pathogenesis of human ulcerative colitis.
|
Proteomics
|
2006
|
1.30
|
|
17
|
Trends in hospitalization rates for inflammatory bowel disease in the United States.
|
Clin Gastroenterol Hepatol
|
2007
|
1.30
|
|
18
|
Results from the 2nd Scientific Workshop of the ECCO. I: Impact of mucosal healing on the course of inflammatory bowel disease.
|
J Crohns Colitis
|
2011
|
1.29
|
|
19
|
CD161 defines a transcriptional and functional phenotype across distinct human T cell lineages.
|
Cell Rep
|
2014
|
1.28
|
|
20
|
Differential protein expression profile in the intestinal epithelium from patients with inflammatory bowel disease.
|
J Proteome Res
|
2007
|
1.13
|
|
21
|
Proteomic analysis of cytokine induced proteins in human intestinal epithelial cells: implications for inflammatory bowel diseases.
|
Proteomics
|
2002
|
1.13
|
|
22
|
Mass Cytometry: Single Cells, Many Features.
|
Cell
|
2016
|
1.13
|
|
23
|
Reciprocal changes of Foxp3 expression in blood and intestinal mucosa in IBD patients responding to infliximab.
|
Inflamm Bowel Dis
|
2010
|
1.10
|
|
24
|
Inflammatory bowel disease: an expanding global health problem.
|
Clin Med Insights Gastroenterol
|
2013
|
1.07
|
|
25
|
Proteomic profiling of mucosal and submucosal colonic tissues yields protein signatures that differentiate the inflammatory colitides.
|
Inflamm Bowel Dis
|
2010
|
1.06
|
|
26
|
Predictive value of epithelial gene expression profiles for response to infliximab in Crohn's disease.
|
Inflamm Bowel Dis
|
2010
|
1.02
|
|
27
|
Proteomic analysis of the intestinal epithelial cell response to enteropathogenic Escherichia coli.
|
J Biol Chem
|
2004
|
1.02
|
|
28
|
Systematic review with network meta-analysis: the efficacy of anti-TNF agents for the treatment of Crohn's disease.
|
Aliment Pharmacol Ther
|
2014
|
1.01
|
|
29
|
Towards personalized care in IBD.
|
Nat Rev Gastroenterol Hepatol
|
2013
|
1.00
|
|
30
|
Host-microbe relationships in inflammatory bowel disease detected by bacterial and metaproteomic analysis of the mucosal-luminal interface.
|
Inflamm Bowel Dis
|
2011
|
0.97
|
|
31
|
Predicting response to Anti-TNF Agents for the treatment of crohn's disease.
|
Therap Adv Gastroenterol
|
2009
|
0.96
|
|
32
|
Proteomics for prediction and characterization of response to infliximab in Crohn's disease: a pilot study.
|
Clin Biochem
|
2008
|
0.95
|
|
33
|
IOIBD technical review on endoscopic indices for Crohn's disease clinical trials.
|
Gut
|
2015
|
0.92
|
|
34
|
Proteomic patterns of colonic mucosal tissues delineate Crohn's colitis and ulcerative colitis.
|
Proteomics Clin Appl
|
2013
|
0.92
|
|
35
|
Serum protein profiling in patients with inflammatory bowel diseases using selective solid-phase bulk extraction, matrix-assisted laser desorption/ionization time-of-flight mass spectrometry and chemometric data analysis.
|
Rapid Commun Mass Spectrom
|
2007
|
0.91
|
|
36
|
Mucosal cytokine gene expression profiles as biomarkers of response to infliximab in ulcerative colitis.
|
Scand J Gastroenterol
|
2012
|
0.90
|
|
37
|
Mass Cytometry of the Human Mucosal Immune System Identifies Tissue- and Disease-Associated Immune Subsets.
|
Immunity
|
2016
|
0.88
|
|
38
|
A systematic review of measurement of endoscopic disease activity and mucosal healing in Crohn's disease: recommendations for clinical trial design.
|
Inflamm Bowel Dis
|
2014
|
0.87
|
|
39
|
TNF-alpha gene expression in colorectal mucosa as a predictor of remission after induction therapy with infliximab in ulcerative colitis.
|
Cytokine
|
2009
|
0.87
|
|
40
|
Differential proteomic analysis of HT29 Cl.16E and intestinal epithelial cells by LC ESI/QTOF mass spectrometry.
|
J Proteomics
|
2009
|
0.87
|
|
41
|
Systematic review: predicting and optimising response to anti-TNF therapy in Crohn's disease - algorithm for practical management.
|
Aliment Pharmacol Ther
|
2015
|
0.85
|
|
42
|
Mass cytometry as a platform for the discovery of cellular biomarkers to guide effective rheumatic disease therapy.
|
Arthritis Res Ther
|
2015
|
0.85
|
|
43
|
Systematic review with meta-analysis: mucosal healing is associated with improved long-term outcomes in Crohn's disease.
|
Aliment Pharmacol Ther
|
2015
|
0.85
|
|
44
|
Label-free quantification for discovering novel biomarkers in the diagnosis and assessment of disease activity in inflammatory bowel disease.
|
J Dig Dis
|
2013
|
0.84
|
|
45
|
Results of the 2nd scientific workshop of the ECCO (III): basic mechanisms of intestinal healing.
|
J Crohns Colitis
|
2011
|
0.83
|
|
46
|
Usefulness of oral beclometasone dipropionate in the treatment of active ulcerative colitis in clinical practice: the RECLICU Study.
|
J Crohns Colitis
|
2010
|
0.82
|
|
47
|
Challenges to the design, execution, and analysis of randomized controlled trials for inflammatory bowel disease.
|
Gastroenterology
|
2012
|
0.82
|
|
48
|
Association Between Response to Etrolizumab and Expression of Integrin αE and Granzyme A in Colon Biopsies of Patients With Ulcerative Colitis.
|
Gastroenterology
|
2015
|
0.81
|
|
49
|
Health Care Cost Analysis in a Population-based Inception Cohort of Inflammatory Bowel Disease Patients in the First Year of Diagnosis.
|
J Crohns Colitis
|
2015
|
0.79
|
|
50
|
Current evidence supporting mucosal healing and deep remission as important treatment goals for inflammatory bowel disease.
|
Expert Rev Gastroenterol Hepatol
|
2016
|
0.77
|
|
51
|
The Risk of Relapse after Anti-TNF Discontinuation in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis.
|
Am J Gastroenterol
|
2016
|
0.77
|
|
52
|
Global mucosal and serum cytokine profile in patients with ulcerative colitis undergoing anti-TNF therapy.
|
Scand J Gastroenterol
|
2015
|
0.76
|
|
53
|
Predicting durable response or resistance to antitumor necrosis factor therapy in inflammatory bowel disease.
|
Therap Adv Gastroenterol
|
2016
|
0.76
|
|
54
|
Clinical Response to Vedolizumab in Ulcerative Colitis Patients Is Associated with Changes in Integrin Expression Profiles.
|
Front Immunol
|
2017
|
0.76
|
|
55
|
Endoscopy in inflammatory bowel disease: advances in disease management.
|
Gastrointest Endosc
|
2017
|
0.75
|
|
56
|
Can We Predict the Efficacy of Anti-TNF-α Agents?
|
Int J Mol Sci
|
2017
|
0.75
|
|
57
|
Advances in the use of biologics and other novel drugs for managing inflammatory bowel disease.
|
Curr Opin Pharmacol
|
2017
|
0.75
|
|
58
|
Combining Flow and Mass Cytometry in the Search for Biomarkers in Chronic Graft-versus-Host Disease.
|
Front Immunol
|
2017
|
0.75
|
|
59
|
Physiological intermolecular modification spectroscopy for the prediction of response to anti-tumor necrosis factor therapy in patients with inflammatory bowel diseases.
|
Dig Dis
|
2014
|
0.75
|
|
60
|
Usefulness of Transcriptional Blood Biomarkers as a Non-invasive Surrogate Marker of Mucosal Healing and Endoscopic Response in Ulcerative Colitis.
|
J Crohns Colitis
|
2017
|
0.75
|
|
61
|
Predictors of tissue healing in ulcerative colitis patients treated with anti-TNF.
|
Dig Liver Dis
|
2016
|
0.75
|
|
62
|
Characterizing unmet medical need and the potential role of new biologic treatment options in patients with ulcerative colitis and Crohn's disease: a systematic review and clinician surveys.
|
Eur J Gastroenterol Hepatol
|
2015
|
0.75
|
|
63
|
Ustekinumab to treat Crohn's disease.
|
Gastroenterol Hepatol
|
2017
|
0.75
|
|
64
|
Efficacy and safety of vedolizumab in the treatment of ulcerative colitis.
|
Gastroenterol Hepatol
|
2016
|
0.75
|
|
65
|
[Vedolizumab in the treatment of Crohn's disease].
|
Gastroenterol Hepatol
|
2015
|
0.75
|
|
66
|
Serum Interleukin 9 Levels Predict Disease Severity and the Clinical Efficacy of Infliximab in Patients with Crohn's Disease.
|
Inflamm Bowel Dis
|
2017
|
0.75
|
|
67
|
The expanding therapeutic armamentarium for inflammatory bowel disease: how to choose the right drug(s) for our patients?
|
J Crohns Colitis
|
2017
|
0.75
|
|
68
|
Serum extracellular vesicles contain protein biomarkers for primary sclerosing cholangitis and cholangiocarcinoma.
|
Hepatology
|
2017
|
0.75
|
|
69
|
Noninvasive biomarkers as surrogate predictors of clinical and endoscopic remission after infliximab induction in patients with refractory ulcerative colitis.
|
Saudi J Gastroenterol
|
2017
|
0.75
|